CSF-1 blockade decreases TAMs. Mice bearing Gl261 tumors were treated with control (n = 5, green bar), dual cediranib+MEDI3617 (n = 5, blue bar), or dual therapy + anti–CSF-1 (n = 5, blue checkered bar) for 10 d before analysis with flow cytometry. The addition of anti–CSF-1 treatment led to a significant decrease in macrophage recruitment compared with control-treatment (*P = 0.0135). Error bars represent the SEM.